Related to its physical properties, heliox gas seems to have a strong and pronounced effect when used in patients with severe lower airway obstruction. However, in the absence of severe lower airway obstruction, there is no advantage to using heliox instead of oxygen as a vehicle of nebulization.
Objective: The authors describe their experience with the use of intravenous ß2 adrenergic (IV terbutaline) in patients admitted to a PICU with severe lower airway obstruction.Patients and methods: A retrospective study of all admissions to a PICU was conducted in Santo Antonio Hospital in Porto Alegre City (Brazil) during the winter of 1995. The files of all the patients that were treated with intravenous ß2 adrenergic as a bronchodilator were selected. The analysis included length of use, initial doses, maximal doses, associated phenomena, arterial blood gases and plasma level of potassium.Results: During the three months of study 367 patients were admitted to the PICU and 38 (10.3%) used IV terbutaline. This group of patients had a mean age of 13.8 ± 12.2 months old and used IV terbutaline for a mean length of 7.24 ± 3.6 days. The initial rate of infusion was 0.55 ± 0.25 mcg/kg/min with a mean therapeutic dose of 2.45 ± 1.18 mcg/kg/min. Twelve patients (31.5%) had increase in their heart rate (over 180 bpm) that prevented increases in the infusion rate. However this was a temporary effect. The patients under 12 months of age started with low infusion rates (0.45 ± 0.22 mcg/kg/min), when compared to children over 1 year old (0.57 ± 0.3 mcg/kg/min), p < 0.01. No patient developed pathologic heart rate attributed to the drug. The serum levels of potassium decreased significantly (p < 0.01) only in the group of patients under 1 year (4.1 ± 0.7 to 3.47 ± 0.52 mEq/L), but this difference had no clinical relevance.Comments: In view of these results the authors showed that the infusion of IV terbutaline in children is safe and presents a low risk if the criteria of administration and monitoring are followed. In this manner, IV terbutaline is an excellent therapeutic option for children with severe lower airway obstruction and no response to the conventional treatment.J. pediatr. (Rio J.). 1998; 74(6): 441-446: asthma, bronchodilators, terbutaline, ß2 adenergics, aerosoltherapy. ResumoObjetivo: Os autores descrevem sua experiência com o uso de ß2 adrenérgico (Terbutalina), por via endovenosa, em pacientes internados em UTI pediátrica com quadro grave de obstrução de vias aéreas inferiores.Pacientes e métodos: Foi realizado um estudo retrospectivo das admissões realizadas na UTI do Hospital da Criança Santo Antônio (HCSA) de Porto Alegre (RS-Brasil) durante o inverno de 1995, sendo selecionados os prontuários dos pacientes que utilizaram ß2 adrenérgi-cos endovenoso, para tratamento de broncoespasmo. Foram analisados dados referentes a tempo de uso, dose inicial, dose máxima utilizada, fenômenos associados, gasometria arterial e níveis séricos de potássio.Resultados: Nos três meses de estudo, foram admitidos 367 pacientes na UTI pediátrica, sendo que 38 (10,3%) vieram a utilizar terbutalina por via endovenosa. Esse grupo tinha uma idade média de 13,8 ± 12,2 meses e utilizou a terbutalina endovenosa por um tempo médio de 7,24 ± 3,6 dias. A taxa inicial de infusão foi de 0,55 ± 0,25 mcg/kg/min, e a dose terapêutic...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.